Nhg Dsrb Continuing Review Report
PARTICIPANT INFORMATION SHEET AND CONSENT FORM
This form is in a format which complies with the 21 mandatory points in the Singapore Good Clinical Practice Guidelines. Please overwrite, insert or delete sections which are not relevant to your study. This template serves to raise for attention crucial elements of Singapore GCP.
If the investigator has a pre-existing Participant Information Sheet format which is demanded by or standard for various external trial designs (e.g., multicentre drug trials), or has another template which conforms to the Singapore GCP guidelines, this can be substituted for this template. However, Investigators are reminded to compare the elements in their PIS forms with this template to ensure that all the key elements are present.
Investigators are reminded to keep the level of language in the Participant Information Form to around the reading level of an 8th to 10th Grade school student. Long technical terms should be avoided or explained in detail. Every effort to ensure the language is clear and simple should be made.
STUDY INFORMATION
Protocol Title:(Use the full protocol title as used in the CIRB Application)
Principal Investigator:
(Please include full name, department, address, phone number*)
(*For all studies, please include minimally your Institution’s mainline. For more than minimal risks studies, please include the mobile number of PI or Study Coordinator, in addition to your Institution’s mainline.)Sponsor:
(Delete this section if this is an investigator-initiated study without specific funding.)
Purpose of the Research Study
You are being invited to participate in a research study.Before you take part in this research study, the study must be explained to you and you must be given the chance to ask questions. Please read carefully the information provided here. If you agree to participate, please sign the consent form. You will be given a copy of this document to take home with you.The purpose of this study is(state what is being studied). We hope to learn (state what the study is designed to discover or establish).
You were selected as a possible participant in this study because (explain why participant is being selected).
This study will recruit (insert number of participant) participants from (state whether from the Principal Investigator's institution, or multiple institutions) over a period of (state recruitment and/or study period). About (state number of participants recruited in this study) participants will be involved in this study.
Study Procedures and Visit Schedule
If you agree to take part in this study, you will be randomised to receive (expand with details of study as necessary). Randomisation means assigning you to one of (insert number of study groups) groups by chance, like tossing a coin or rolling dice. (Delete para if there is no randomization.)If you agree to take part in this study, you will be asked to (insert brief explanation of study procedures here)).
Your participation in the study will last (insert length of time participant will be required for the study). You will (take the study medication / use the study device) for about (insert number of times study intervention will be performed) and be followed up for (state length of time of follow-up within the study). You will need to visit the doctor’s office (state number of times) times in the course of the study.
(For studies with multiple visits, you may want to consider presenting the information in table format indicating what will happen at each visit.)
Schedule of visits and procedures:
Visit 1:
Visit 2, 3 (Weeks ___, ___) etc.
Final Visit (Week ___)
Follow-up: The follow-up part consists of (state number of contacts)
(For videotaping, please submit a separate consent form.)
(If you are collecting blood samples, state how many blood specimens are required and the amount in teaspoons as part of this study.)
When your participation in the study ends, you will no longer have access to (the study medication/device), unless special additional arrangements are made by the Principal Investigator.
Any blood or tissue specimens obtained during the course of this study will be stored and analysed only for the purposes of this study for a period not exceeding (Insert intended duration of storage), and will be destroyed after completion of the study.
- Provision for re-identification in the case of an incidental finding if the proposed research expressly provides for such re-identification.
(a)Specific purpose for which the tissues or blood samples will be used, if this information is available; but if not available, the purpose may be stated as for general research;
(b)Period of storage;
(c)Provisions to ensure privacy and confidentiality;
(d)Provision for re-identification in the case of an incidental finding if the future research expressly provides for such re-identification; and
(e)Whether the tissues or blood samples will be transferred outside of Singapore.).
Your Responsibilities in this Study
If you agree to participate in this study, you should (choose applicable points):- Take the study drug as instructed and follow the advice given to you by the study team. (if device/others explain what is required for study compliance).
- Keep your study appointments. If it is necessary to miss an appointment, please contact the study staff to reschedule as soon as you know you will miss the appointment.
- Inform the Principal Investigator as soon as possible about any side effects that you may have encountered.
- Be prepared to visit the hospital (insert number of visits) and undergo all the procedures that are outlined above.
What is Not Standard Care or Experimental in this Study
The study is being conducted because (the intervention or device) is not yet proven to be a standard (investigation, treatment) in participants with (condition under investigation in this study). We hope that your participation will help us to determine whether (investigation or treatment) is equal or superior to existing (investigation or treatment).Use of a placebo (inactive agent), blinding (one or more parties unaware of the treatment assignment), and randomization (study drug selection by chance) are only done for research studies. (Modify as relevant for your study.)
Although (Investigation or Treatment) may be part of standard medical care, in this study this / these procedure(s) are being performed for the purposes of the research.
Possible Risks, Discomforts and Inconveniences
- Describe the discomforts and inconveniences reasonably expected.
- Describe the expected adverse outcomes (to exclude what is possible but unexpected).
- Describe any reasonably foreseeable risks. Note that if this is a placebo-controlled study, there may be the risk that the existing disease/condition may go untreated and the participant’s condition may worsen.
- Include a statement that the particular treatment or procedure may involve risks to the participant, which are currently unforeseeable.
- Note: this section should also describe the risks associated with other medications used in the study, other procedures done (i.e., venipuncture, concomitant medications, exposure to radiation, etc.).
Potential Benefits
If you participate in this study you may reasonably expect to benefit from the study (investigation / intervention / drug) in the following way: (explain how participant might benefit)OR
There is no assurance you will benefit from this study. However, your participation may add to the medical knowledge about the use of this (medication / device / intervention /investigation).
OR
There is no known benefit from participation in this study. However, your participation in this study may add to the medical knowledge about the use of this (medication / device / intervention / investigation).
Important Information for Women Participant
(Delete or modify as necessary). .The effect of (the study drug/intervention/investigation) on a baby's development is not known. Therefore, pregnant and breast-feeding women may not take part in this study. Women who have a chance of becoming pregnant must have a negative pregnancy test at study entry and use birth control during the study. If you become pregnant during this study, you must stop taking (the study drug) and call your doctor or the Principal Investigator immediately.
Alternatives
(Delete or modify as necessary).If you choose not to take part in this study, the alternative is to have what is considered standard care for your condition. In our institution this would be (investigation / treatment / procedure).
This alternative procedure has the following potential benefits:
(Insert list of possible benefits of the alternatives, which may be the standard of care)
and the following potential risks:
(Insert list of possible risks from the alternatives)
(Note: While the standard care is mentioned in this section as the “alternative”, the investigators should explain to the participant in such a way that the participant understands that the research intervention/procedures/tests is the alternative to the standard care that is being offered to the participant.)
Costs of Participation
If you take part in this study, the following will be performed at no charge to you: (Insert list of procedures / drugs/ tests for which the participant will NOT pay)If you take part in this study, you will have to pay for the following: (Insert list of procedures / drugs/ tests for which the participant WILL be required to pay)
You will be reimbursed for your time, inconvenience and transportation costs as follows:
- If you complete the study, you will be paid (Insert payment amount).
- If you do not complete the study for any reason, you will be paid (Insert payment amount) for each visit you complete.
ParticipaNT’S RIGHTS
Your participation in this study is entirely voluntary. Your questions will be answered clearly and to your satisfaction.
In the event of any new information becoming available that may be relevant to your willingness to continue in this study, you (or your legally acceptable representative, if relevant) will be informed in a timely manner by the Principal Investigator or his/her representative and further consent may be required.
(Delete or modify as necessary). In the event of changes to the development of capacity by minors to made decisions (e.g. the participant reaches the age of 21 years old), the participant would be contacted for further consent.
.
The pTin ininthe In the
By signing and participating in the study, you do not waive any of your legal rights to revoke your consent and withdraw from the study at any time.
WITHDRAWAL FROM STUDY
You are free to withdraw your consent and discontinue your participation at any time without prejudice to you or effect on your medical care. If you decide to stop taking part in this study, you should tell the Principal Investigator.If you withdraw from the study, or the study medication is stopped for any reason,
- (Add anticipated consequences, if any, of discontinuing the study drug or device).
- (Clearly state the protocol-specific termination procedures).
- (Return all study -related supplies, including unused study drug).
(Insert this statement if any biological samples will be collected.)
The biological samples collected for the study will be deemed to be given to (name of institution/sponsor) and will not be returned to you. However, you retain your right to ask the Principal Investigator to discard or destroy any remaining samples if they have not been anonymised.
Your doctor, the Principal Investigator and/or the Sponsor of this study may stop your participation in the study at any time for one or more of the following reasons: (You may use these reasons and/or add some of your own.)
- Failure to follow the instructions of the Principal Investigator and/or study staff.
- The Principal Investigator decides that continuing your participation could be harmful.
- Pregnancy (if applicable.)
- You need treatment not allowed in the study.
- The study is cancelled.
Research Related Injury and Compensation
(For PI-Initiated studies, please use the following 2 paragraphs):The Hospital does not make any provisions to compensate study participants for research related injury. However, compensation may be considered on a case-by-case basis for unexpected injuries due to non-negligent causes.
By signing the Consent Form, you will not waive any of your legal rights or release the parties involved in this study from liability for negligence.
(For sponsored studies, following the ABPI Guidelines for compensation, please use the following 2 paragraphs):
Compensation for the research related injury shall be paid by Institution/ Sponsor Name according to the Association of the British Pharmaceutical Industry’s Clinical Trial Compensation Guidelines. Broadly speaking, the ABPI guidelines recommend that without legal commitment, participants should be compensated by Institution/ Sponsor Name without having to prove that Institution/ Sponsor Name is at fault. There are limitations to compensation in the ABPI guidelines. A copy of the ABPI guidelines will be provided to you upon request.
By signing the Consent Form, you will not waive any of your legal rights or release the parties involved in this study from liability for negligence.
Confidentiality of Study and Medical Records
Your participation in this study will involve the collection of Personal Data. Personal Data collected for this study will be kept confidential. Your records, to the extent of the applicable laws and regulations, will not be made publicly available. Only your Investigator(s) will have access to the confidential information being collected.However, the Sponsoring company (Name of company, if relevant), Regulatory Agencies, Institutional Review Board and Ministry of Health will be granted direct access to your original medical records to check study procedures and data, without making any of your information public.
By signing the Consent Form, you consent to (i) the collection, access to, use and storage of your Personal Data by (Name of Institution), and (ii) the disclosure of such Personal Data to our authorised service providers and relevant third parties for the purpose of future research studies (“Future Research”).
“Personal Data” means data about you which makes you identifiable (i) from such data or (ii) from that data and other information which an organisation has or likely to have access. Examples of personal data include medical conditions, medications, investigations and treatment history.
Research arising in the future, based on this “Personal Data”, will be subject to review by the relevant institutional review board.
Data collected and entered into the (Case Report Form(s) or Data Collection Form(s)) are the property of (Institution or Company). In the event of any publication regarding this study, your identity will remain confidential.
(If Investigators intend to transfer biological samples and/or data out of Singapore, please include either of the statements where relevant):
Any biological samples and/or information containing your “Personal Data” that is collected for the purposes described in this Participant Information Sheet and Consent Form will be stored in Singapore. Only anonymised biological samples and/or data will be transferred out of Singapore to (Insert Name of overseas collaborator/company).
OR
Your biological samples and/or information containing your “Personal Data” will be transferred out of Singapore to (Insert Name of overseas collaborator/company) for the purposes described in this Participant Information Sheet and Consent Form. (Name of institution transferring the samples and/or data) will take appropriate steps to ensure it complies with the data protection requirements in the Personal Data Protection Act while your ‘Personal Data” to be transferred remains in its possession or under its control.
By participating in this research study, you are confirming that you have read, understood and consent to the SingHealth Data Protection Policy, the full version of which is available at
Who to Contact if You Have Questions Regarding the Study
If you have questions about this research study or in the case of any injuries during the course of this study, you may contact the Principal Investigator (Insert Name and contact Details here).(For all studies, please include minimally your Institution’s mainline. For more than minimal risk studies, please include the mobile number of PI or Study Coordinator, in addition to your Institution’s mainline).
Who Has Reviewed the Study
This study has been reviewed by the SingHealth Centralised Institutional Review Board for ethics approval.